**5. References**


Toxoplasmosis: Advances and Vaccine Perspectives 181

Dunachie, S. J. and A. V. Hill (2003). "Prime-boost strategies for malaria vaccine

Duquesne, V., C. Auriault, et al. (1991). "Identification of T cell epitopes within a 23-kD antigen (P24) of Toxoplasma gondii." *Clin Exp Immunol* 84(3): 527-534. Fang, R., H. Feng, et al. (2010). "Construction and immunogenicity of pseudotype

Fang, R., H. Nie, et al. (2009). "Protective immune response in BALB/c mice induced by a

Gazzinelli, R., Y. Xu, et al. (1992). "Simultaneous depletion of CD4+ and CD8+ T

Gazzinelli, R. T., D. Amichay, et al. (1996). "Role of macrophage-derived cytokines in the

Gazzinelli, R. T., M. Wysocka, et al. (1994). "Parasite-induced IL-12 stimulates early IFN-

Gigley, J. P., B. A. Fox, et al. (2009). "Long-term immunity to lethal acute or chronic type II

Greenland, J. R. and N. L. Letvin (2007). "Chemical adjuvants for plasmid DNA vaccines."

Grillot-Courvalin, C., S. Goussard, et al. (1999). "Bacteria as gene delivery vectors for

Grillot-Courvalin, C., S. Goussard, et al. (2002). "Wild-type intracellular bacteria deliver

Gwadz, R. W., A. H. Cochrane, et al. (1979). "Preliminary studies on vaccination of rhesus

Hill, D., C. Coss, et al. (2011). "Identification of a sporozoite-specific antigen from

Hiramoto, R. M., A. J. Galisteo, et al. (2002). "200 Gy sterilised Toxoplasma gondii

Hoseinian Khosroshahi, K., F. Ghaffarifar, et al. (2011). "Evaluation of the immune response

monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites." *Bull World Health Organ* 57 Suppl 1: 165-173. Hakim, F. T., R. T. Gazzinelli, et al. (1991). "CD8+ T cells from mice vaccinated against

Toxoplasma gondii are cytotoxic for parasite-infected or antigen-pulsed host cells."

tachyzoites maintain metabolic functions and mammalian cell invasion, eliciting cellular immunity and cytokine response similar to natural infection in mice."

induced by DNA vaccine cocktail expressing complete SAG1 and ROP2 genes

mammalian cells." *Curr Opin Biotechnol* 10(5): 477-481.

Toxoplasma gondii." *J Parasitol* 97(2): 328-337.

against toxoplasmosis." *Vaccine* 29(4): 778-783.

DNA into mammalian cells." *Cell Microbiol* 4(3): 177-186.

baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model."

suicidal DNA vaccine of the MIC3 gene of Toxoplasma gondii." *Vet Parasitol* 164(2-

lymphocytes is required to reactivate chronic infection with Toxoplasma gondii." *J* 

induction and regulation of cell-mediated immunity to Toxoplasma gondii." *Curr* 

gamma synthesis and resistance during acute infection with Toxoplasma gondii." *J* 

Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain." *Infect* 

development." *J Exp Biol* 206(Pt 21): 3771-3779.

*Vaccine* 28(7): 1803-1807.

*Immunol* 149(1): 175-180.

*Immunol* 153(6): 2533-2543.

*Immun* 77(12): 5380-5388.

*Vaccine* 25(19): 3731-3741.

*J Immunol* 147(7): 2310-2316.

*Vaccine* 20(16): 2072-2081.

*Top Microbiol Immunol* 219: 127-139.

4): 134-140.


Bhopale, G. M. (2003). "Development of a vaccine for toxoplasmosis: current status."

Boothroyd, J. C. (2009). "Toxoplasma gondii: 25 years and 25 major advances for the field."

Bourguin, I., T. Chardes, et al. (1993). "Oral immunization with Toxoplasma gondii antigens

Bourguin, I., T. Chardes, et al. (1991). "Amplification of the secretory IgA response to Toxoplasma gondii using cholera toxin." *FEMS Microbiol Lett* 65(3): 265-271. Buxton, D. (1993). "Toxoplasmosis: the first commercial vaccine." *Parasitol Today* 9(9): 335-

Caetano, B. C., O. Bruna-Romero, et al. (2006). "Vaccination with replication-deficient

Chen, R., S. H. Lu, et al. (2009). "Protective effect of DNA-mediated immunization with

Cong, H., E. J. Mui, et al. (2011). "Towards an immunosense vaccine to prevent

Crampton, A. and T. Vanniasinkam (2007). "Parasite vaccines: the new generation." *Infect* 

Cutchins, E. C. and J. Warren (1956). "Immunity patterns in the guinea pig following

Denkers, E. Y. and R. T. Gazzinelli (1998). "Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection." *Clin Microbiol Rev* 11(4): 569-588. Denkers, E. Y., R. T. Gazzinelli, et al. (1993). "Bone marrow macrophages process exogenous

Denkers, E. Y., R. T. Gazzinelli, et al. (1993). "Emergence of NK1.1+ cells as effectors of IFN-

Dondji, B., E. Perez-Jimenez, et al. (2005). "Heterologous prime-boost vaccination with the

Doria-Rose, N. A. and N. L. Haigwood (2003). "DNA vaccine strategies: candidates for immune modulation and immunization regimens." *Methods* 31(3): 207-216. Dubey, J. P., M. C. Jenkins, et al. (1996). "Killing of Toxoplasma gondii oocysts by irradiation

Dubey, J. P., J. K. Lunney, et al. (1998). "Immunity to toxoplasmosis in pigs fed irradiated

Toxoplasma gondii oocysts." *J Parasitol* 84(4): 749-752.

immunity in C57BL/6 mice." *Infect Immun* 61(5): 2082-2088.

in association with cholera toxin induces enhanced protective and cell-mediated

recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice." *Hum* 

liposome-encapsulated GRA4 against infection of Toxoplasma gondii." *J Zhejiang* 

toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A\*0201."

Toxoplasma infection and vaccination with killed Toxoplasma." *Am J Trop Med Hyg*

Toxoplasma gondii polypeptides for recognition by parasite-specific cytolytic T

gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice."

LACK antigen protects against murine visceral leishmaniasis." *Infect Immun* 73(8):

and protective immunity induced by vaccination with irradiated oocysts." *J* 

*Microbes Infect* 5(5): 457-462.

*Int J Parasitol* 39(8): 935-946.

*Gene Ther* 17(4): 415-426.

*Univ Sci B* 10(7): 512-521.

*Vaccine* 29(4): 754-762.

*Genet Evol* 7(5): 664-673.

lymphocytes." *J Immunol* 150(2): 517-526.

*J Exp Med* 178(5): 1465-1472.

*Parasitol* 82(5): 724-727.

5(2): 197-209.

5286-5289.

337.


Toxoplasmosis: Advances and Vaccine Perspectives 183

Mevelec, M. N., C. Ducournau, et al. (2010). "Mic1-3 Knockout Toxoplasma gondii is a good

Nussenzweig, R. S., J. Vanderberg, et al. (1967). "Protective immunity produced by the

Omata, Y., Y. Aihara, et al. (1996). "Toxoplasma gondii: experimental infection in cats vaccinated with 60Co-irradiated tachyzoites." *Vet Parasitol* 65(3-4): 173-183. Pifer, R. and F. Yarovinsky (2011). "Innate responses to Toxoplasma gondii in mice and

Qu, D., S. Wang, et al. (2008). "Protective effect of a DNA vaccine delivered in attenuated

Qu, D., H. Yu, et al. (2009). "Induction of protective immunity by multiantigenic DNA

Rocha, C. D., B. C. Caetano, et al. (2004). "Recombinant viruses as tools to induce protective cellular immunity against infectious diseases." *Int Microbiol* 7(2): 83-94. Rosenberg, C., S. De Craeye, et al. (2009). "Induction of partial protection against infection

Seah, S. K. and G. Hucal (1975). "The use of irradiated vaccine in immunization against experimental murine toxoplasmosis." *Can J Microbiol* 21(9): 1379-1385. Shang, L., Q. Liu, et al. (2009). "Protection in mice immunized with a heterologous prime-

Tan, T. G., E. Mui, et al. (2010). "Identification of T. gondii epitopes, adjuvants, and host

Ulmer, J. B., B. Wahren, et al. (2006). "Gene-based vaccines: recent technical and clinical

van Drunen Littel-van den Hurk, S., S. L. Babiuk, et al. (2004). "Strategies for improved

Wang, H., S. He, et al. (2009). "Toxoplasma gondii: protective effect of an intranasal SAG1

Xiang, W., Z. Qiong, et al. (2009). "The location of invasion-related protein MIC3 of

Xue, M., S. He, et al. (2008). "Evaluation of the immune response elicited by multi-antigenic

and MIC4 DNA vaccine in mice." *Exp Parasitol* 122(3): 226-232.

gondii infection in mice." *Vet Parasitol* 166(3-4): 220-227.

chimeric tachyzoite antigens." *Vaccine* 27(18): 2489-2498.

advances." *Trends Mol Med* 12(5): 216-222.

against Toxoplasma gondii challenge." *Vaccine* 27(21): 2741-2745.

4499.

49.

162.

3989.

*Rev* 199: 113-125.

166(1-2): 1-7.

*Parasitol Int* 57(4): 424-429.

humans." *Trends Parasitol*.

26(35): 4541-4548.

against acute, chronical and congenital toxoplasmosis in mice." *Vaccine* 23(36): 4489-

candidate for a vaccine against T. gondii-induced abortion in sheep." *Vet Res* 41(4):

injection of x-irradiated sporozoites of plasmodium berghei." *Nature* 216(5111): 160-

Salmonella typhimurium against Toxoplasma gondii infection in mice." *Vaccine*

vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma

with Toxoplasma gondii genotype II by DNA vaccination with recombinant

boost regime using DNA and recombinant pseudorabies expressing TgSAG1

genetic factors that influence protection of mice and humans." *Vaccine* 28(23): 3977-

formulation and delivery of DNA vaccines to veterinary target species." *Immunol* 

Toxoplasma gondii and protective effect of its DNA vaccine in mice." *Vet Parasitol*

DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii."


Hutson, S. L., E. Mui, et al. (2010). "T. gondii RP promoters & knockdown reveal molecular

Ishii, K., H. Hisaeda, et al. (2006). "The involvement of immunoproteasomes in induction of

Ismael, A. B., D. Hedhli, et al. (2009). "Further analysis of protection induced by the MIC3

Ismael, A. B., D. Sekkai, et al. (2003). "The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis." *Infect Immun* 71(11): 6222-6228. Jongert, E., S. de Craeye, et al. (2007). "GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii." *Parasite Immunol* 29(9): 445-453. Jongert, E., C. W. Roberts, et al. (2009). "Vaccines against Toxoplasma gondii: challenges and

Kang, H., J. S. Remington, et al. (2000). "Decreased resistance of B cell-deficient mice to

Liu, Q., L. Shang, et al. (2010). "The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18." *Res Vet Sci* 89(1): 93-97. Liu, S., L. Shi, et al. (2009). "Evaluation of protective effect of multi-epitope DNA vaccine

Lu, F., S. Huang, et al. (2009). "The temperature-sensitive mutants of Toxoplasma gondii and

Ma, G. Y., J. Z. Zhang, et al. (2009). "Toxoplasma gondii: proteomic analysis of antigenicity

Machado, A. V., B. C. Caetano, et al. (2010). "Prime and boost immunization with influenza

McLeod, R., J. K. Frenkel, et al. (1988). "Subcutaneous and intestinal vaccination with

Mendes, E. A., B. C. Caetano, et al. (2011). "MyD88-dependent protective immunity elicited

Mevelec, M. N., D. Bout, et al. (2005). "Evaluation of protective effect of DNA vaccination

infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase." *J Immunol* 164(5): 2629-2634. Krahenbuhl, J. L., J. Ruskin, et al. (1972). "The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii." *J Immunol* 108(2): 425-431. Liu, Q., S. Gao, et al. (2008). "A recombinant pseudorabies virus expressing TgSAG1 protects

against challenge with the virulent Toxoplasma gondii RH strain and pseudorabies

encoding six antigen segments of Toxoplasma gondii in mice." *Parasitol Res* 105(1):

and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces

tachyzoites of Toxoplasma gondii and acquisition of immunity to peroral and

by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is

with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid,

MIC3 conferred protection." *Vaccine* 27(22): 2959-2966.

opportunities." *Mem Inst Oswaldo Cruz* 104(2): 252-266.

in BALB/c mice." *Microbes Infect* 10(12-13): 1355-1362.

ocular toxoplasmosis." *Vaccine* 27(4): 573-580.

of soluble tachyzoite antigen." *Exp Parasitol* 122(1): 41-46.

strong protective immunity." *Vaccine* 28(18): 3247-3256.

congenital toxoplasma challenge." *J Immunol* 140(5): 1632-1637.

mediated by CD8(+) T lymphocytes." *Vaccine* 29(27): 4476-4484.

e14057.

1045-1053.

267-274.

pathways associated with proliferation and cell-cycle arrest." *PLoS One* 5(11):

MHC class I-restricted immunity targeting Toxoplasma SAG1." *Microbes Infect* 8(4):

DNA vaccine against T. gondii: CD4 and CD8 T cells are the major effectors of the MIC3 DNA vaccine-induced protection, both Lectin-like and EGF-like domains of against acute, chronical and congenital toxoplasmosis in mice." *Vaccine* 23(36): 4489- 4499.


**13** 

*Alcalá University* 

*Spain* 

**Screening of the Prevalence of Antibodies** 

In the recent decades it has been found the occurrence of a large number of hitherto unknown or undervalued pathogens, and they present a risk to health and human welfare. Almost all incidents caused by emerging pathogens have been attached to zoonotic agents, which expanded its host range and are capable of breaching the species barrier (Zeier et al., 2005). Besides the known diseases, new ones emerge or reemerge due to a variety of socioeconomic, health and environmental questions. This increase in communicable diseases has serious implications for public health and animal health (Chomel, 1998; Daszak et al., 2000, Cleaveland et al., 2001, Simpson, 2002; Daszak & Cunningham, 2003; Zeier et al., 2005;

Emerging zoonoses are also a public health problem, the biggest threat to animal welfare, environmental quality and conservation of biodiversity (Daszak et al., 2000; Cunningham, 2005, Briones et al., 2002). The expected increase contact between humans and wildlife, caused by anthropogenic interference in the ecosystem, increase the emergence of pathogens originating in wildlife cycles, which can cross-infect man and animals (Bengis et al., 2004). Thus, wildlife is a constant source of "zoonotic pool" that plays a fundamental role in human

In the recent past, the diseases of wild animals have been important only when they threatened livestock or human health (Daszak et al., 2000), but outbreaks in endangered species have led to them having more significant consideration. Currently, these diseases are booming, especially in the space where interaction occurs between wildlife and farm animals, including an increase in contact between them and the man (Simpson, 2002; Gortázar et al., 2007). Arthropod-borne diseases represent the most common zoonosis in relation to wildlife in the northern hemisphere, especially the Old World (Lindgren et al., 2000), so infectious agents are diverse and constantly growing, so their relationship would

Wild animals and arthropod vectors play also important roles in the exposure of humans and domestic animals to animal-borne pathogens (Morse, 1995). Contact between humans and wild animals may occur when people venture into the latter's ecosystems, such contact in foreseen as a future generator of cross infestation, but the knowledge of ectoparasites, with special mention to ticks and their hosts' reservoirs that are located in many areas of

Cunningham, 2005; Blancou et al., 2005, Gibbs, 2005; Gortázar et al., 2007).

exposure to infectious agents against novel animal (Morse, 1995).

**1. Introduction** 

be endless (Bueno et al., 2009).

 **to the Tick** *Hyalomma lusitanicum*

Consuelo Giménez Pardo and Lourdes Lledó García

**in a Province of Northern Spain** 

